Supplementary Table 1 - FON-2021-1406 - INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
收藏DataCite Commons2024-05-16 更新2025-04-15 收录
下载链接：
https://tandf.figshare.com/articles/dataset/Supplementary_Table_1_-_FON-2021-1406_-_INSIGHT_2_A_Phase_II_study_of_tepotinib_plus_osimertinib_in_MET-amplified_NSCLC_and_first-line_osimertinib_resistance/17261561/1
下载链接
链接失效反馈官方服务：
资源简介：
Table
S1. Clinical outcomes with first-, second- and third-generation EGFR TKIs
received as first-line therapy in randomized controlled clinical trials of
EGFR TKIs in EGFR-mutant advanced NSCLC [1–22]
EGFR: epidermal growth factor receptor; NSCLC:
non-small cell lung cancer; ORR: objective response rate; OS: overall
survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor.
INSIGHT 2: A Phase II study of tepotinib plus
osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
提供机构：
Taylor & Francis
创建时间：
2022-05-03
